197 related articles for article (PubMed ID: 23821159)
1. Development of a novel regulatory pharmacovigilance prioritisation system: an evaluation of its performance at the UK Medicines and Healthcare products Regulatory Agency.
Seabroke S; Wise L; Waller P
Drug Saf; 2013 Oct; 36(10):1025-32. PubMed ID: 23821159
[TBL] [Abstract][Full Text] [Related]
2. A descriptive analysis of medicines safety advisories issued by national medicines regulators in Australia, Canada, the United Kingdom and the United States - 2007 to 2016.
Perry LT; Bhasale A; Fabbri A; Lexchin J; Puil L; Joarder M; Mintzes B
Pharmacoepidemiol Drug Saf; 2020 Sep; 29(9):1054-1063. PubMed ID: 32696556
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
4. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
[TBL] [Abstract][Full Text] [Related]
5. Comparative Assessment of the National Pharmacovigilance Systems in East Africa: Ethiopia, Kenya, Rwanda and Tanzania.
Barry A; Olsson S; Minzi O; Bienvenu E; Makonnen E; Kamuhabwa A; Oluka M; Guantai A; Bergman U; van Puijenbroek E; Gurumurthy P; Aklillu E
Drug Saf; 2020 Apr; 43(4):339-350. PubMed ID: 31919794
[TBL] [Abstract][Full Text] [Related]
6. A review of the National pharmacovigilance system in Malta - implementing and operating a pharmacovigilance management system.
Tanti A; Micallef B; Serracino-Inglott A; Borg JJ
Expert Opin Drug Saf; 2017 Jan; 16(1):65-76. PubMed ID: 27732110
[TBL] [Abstract][Full Text] [Related]
7. Testing and implementing signal impact analysis in a regulatory setting: results of a pilot study.
Heeley E; Waller P; Moseley J
Drug Saf; 2005; 28(10):901-6. PubMed ID: 16180939
[TBL] [Abstract][Full Text] [Related]
8. [Direct reporting by patients of adverse drug reactions in Spain].
Esther Salgueiro M; Jimeno FJ; Aguirre C; García M; Ordóñez L; Manso G
Farm Hosp; 2013; 37(1):65-71. PubMed ID: 23461502
[TBL] [Abstract][Full Text] [Related]
9. Identification of Substandard Medicines via Disproportionality Analysis of Individual Case Safety Reports.
Trippe ZA; Brendani B; Meier C; Lewis D
Drug Saf; 2017 Apr; 40(4):293-303. PubMed ID: 28130773
[TBL] [Abstract][Full Text] [Related]
10. Early communication of drug safety concerns: a feasibility study on enhancing interaction between the pharmaceutical industry and regulators.
Swain E; Morgan S; Brewster W; Kauser S
Pharmacoepidemiol Drug Saf; 2010 Mar; 19(3):232-7. PubMed ID: 20033909
[TBL] [Abstract][Full Text] [Related]
11. Enhancing Pharmacovigilance in Sub-Saharan Africa Through Training and Mentoring: A GSK Pilot Initiative in Malawi.
Jusot V; Chimimba F; Dzabala N; Menang O; Cole J; Gardiner G; Ofori-Anyinam O; Oladehin O; Sambakunsi C; Kawaye M; Stegmann JU; Guerra Mendoza Y
Drug Saf; 2020 Jun; 43(6):583-593. PubMed ID: 32239447
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological prioritisation of signals of disproportionate reporting: proposal of an algorithm and pilot evaluation.
Salvo F; Raschi E; Moretti U; Chiarolanza A; Fourrier-Réglat A; Moore N; Sturkemboom M; De Ponti F; Poluzzi E; Pariente A
Eur J Clin Pharmacol; 2014 May; 70(5):617-25. PubMed ID: 24595599
[TBL] [Abstract][Full Text] [Related]
13. Aggregate analysis of regulatory authority assessors' comments to improve the quality of periodic safety update reports.
Jullian S; Jaskiewicz L; Pfannkuche HJ; Parker J; Lalande-Luesink I; Lewis DJ; Close P
Pharmacoepidemiol Drug Saf; 2015 Sep; 24(9):971-9. PubMed ID: 26175055
[TBL] [Abstract][Full Text] [Related]
14. Pharmacovigilance in China: development and challenges.
Zhao Y; Wang T; Li G; Sun S
Int J Clin Pharm; 2018 Aug; 40(4):823-831. PubMed ID: 30051225
[TBL] [Abstract][Full Text] [Related]
15. Pharmacovigilance and communicating safety information.
Drug Ther Bull; 2012 Dec; 50(12):138-40. PubMed ID: 23241564
[TBL] [Abstract][Full Text] [Related]
16. Comparison of three methods (an updated logistic probabilistic method, the Naranjo and Liverpool algorithms) for the evaluation of routine pharmacovigilance case reports using consensual expert judgement as reference.
Théophile H; André M; Miremont-Salamé G; Arimone Y; Bégaud B
Drug Saf; 2013 Oct; 36(10):1033-44. PubMed ID: 23828659
[TBL] [Abstract][Full Text] [Related]
17. The reorganisation of European pharmacovigilance. Part 2. From spontaneous reports to agency reviews and decisions.
Prescrire Int; 2015 Feb; 24(157):50-4. PubMed ID: 25802924
[TBL] [Abstract][Full Text] [Related]
18. The importance of direct patient reporting of suspected adverse drug reactions: a patient perspective.
Anderson C; Krska J; Murphy E; Avery A;
Br J Clin Pharmacol; 2011 Nov; 72(5):806-22. PubMed ID: 21496066
[TBL] [Abstract][Full Text] [Related]
19. Pharmacovigilance Discussion Forum--The European Generic Medicines Association's 8th Annual Meeting (January 21, 2015--London, UK).
Lam S
Drugs Today (Barc); 2015 Jan; 51(1):89-92. PubMed ID: 25685861
[TBL] [Abstract][Full Text] [Related]
20. Adverse drug reactions reporting in Calabria (Southern Italy) in the four-year period 2011-2014: impact of a regional pharmacovigilance project in light of the new European Legislation.
Leporini C; Marrazzo G; Mumoli L; Esposito S; Gallelli L; Mangano G; Brancati G; De Francesco EA; Russo E; De Sarro G;
Expert Opin Drug Saf; 2017 May; 16(5):515-522. PubMed ID: 28395523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
